BiomX - רווח למניה אחת ב-12 החודשים האחרונים PHGE

BiomX Inc. relies on patent protection for viruses and grants, which stabilizes its share price. However, intense competition from new antibiotics creates risks. Active Phase II studies to combat resistance drive the development dynamics. The historical year-over-year EPS growth (TTM) illustrates the current trend, where the value has settled at -12.60, helping to assess profit sustainability.

Investors view BiomX Inc. (PHGE) as a high-risk asset, meaning that analyzing the year-over-year EPS (TTM) allows for tracking the net income per share over the last four quarters without time gaps. This indicator demonstrates the company's ability to generate income amidst fierce competition with antibiotic manufacturers, determining the financial stability of this niche biotech startup.